MIOX Human

Myo-Inositol Oxygenase (MIOX) is an enzyme that plays a crucial role in the metabolism of myo-inositol, a compound involved in various cellular processes. This enzyme is particularly significant in the context of kidney function and has been studied extensively as a potential biomarker for acute kidney injury (AKI).

MIOX was identified as a kidney-specific protein, predominantly expressed in the proximal renal tubules . Its role in converting myo-inositol to glucuronic acid is essential for maintaining cellular homeostasis. The enzyme’s specificity to kidney tissue makes it a valuable marker for renal health, particularly in diagnosing and monitoring AKI .

Human recombinant MIOX is produced using recombinant DNA technology, which involves inserting the gene encoding MIOX into a suitable expression system, such as bacteria or yeast. This allows for the large-scale production of the enzyme, facilitating its use in research and clinical applications.

MIOX has emerged as a promising biomarker for AKI due to its early and specific response to renal injury. Studies have shown that MIOX levels in plasma increase significantly before the rise in traditional markers like creatinine, providing a potential window for early therapeutic intervention . This early detection is crucial for improving patient outcomes and reducing the morbidity and mortality associated with AKI.

Research on MIOX has focused on developing sensitive and specific assays to measure its levels in biological samples. Techniques such as immunoassays and LC-MS/MS have been employed to quantify MIOX, demonstrating its potential as a reliable biomarker for kidney function .